CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
Capecitabine improves disease‑free survival and overall survival in early‑stage breast cancer patients with residual disease after standard neoadjuvant therapy.
Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti‑cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5‑Fluorouracil, has been approved for treating metastatic breast cancer. One randomized clinical trial (CREATE‑X) of capecitabine versus no additional therapy has been conducted in women with early stage breast cancer who received standard chemotherapy pre‑operative therapy and had residual invasive breast cancer at the time of surgery. Results from CREATE‑X, showed that capecitabine had a statistically significant survival advantage compared with no additional therapy. This perspective provides a review and analysis of the available data from CREATEx in the context of results from other adjuvant trials of capecitabine in early stage breast cancer that had disease‑free survival as a primary endpoint. We conclude that although the previously published studies of capecitabine in the adjuvant setting did not meet their primary endpoint, the data from these studies are consistent with the hypothesis that capecitabine may offer additional survival benefit in patients with chemo‑refractory breast cancer at the time of surgery after receiving standard chemotherapy. In these patients, offering a course of adjuvant capecitabine or enrolling the patient in a clinical trial are appropriate therapeutic options. The patient should be informed about both the increased survival observed in the CREATEx trial and the expected toxicities from capecitabine chemotherapy.
The CREATE‑X trial demonstrates that adjuvant capecitabine improves survival for patients with residual disease after standard chemotherapy, providing a new therapeutic option for high‑risk early‑stage breast cancer.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC